{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:15:38Z","timestamp":1790964938779,"version":"4.1.0"},"reference-count":55,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Helis Foundation and Cancer Prevention and Research Institute of Texas (CPRIT)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: With the rise in prevalence of diagnostic genetic techniques like RNA sequencing and whole exome sequencing (WES), as well as biological treatment regiments for cancer therapy, several genes have been implicated in carcinogenesis. This review aims to update our understanding of the Neurofibromatosis 2 (NF2) gene and its role in the pathogenesis of various cancers. Methods: A comprehensive search of five online databases yielded 43 studies that highlighted the effect of sporadic NF2 mutations on several cancers, including sporadic meningioma, ependymoma, schwannoma, mesothelioma, breast cancer, hepatocellular carcinoma, prostate cancer, glioblastoma, thyroid cancer, and melanoma. Of note were key biological pathways implicated in cancer formation resulting from sporadic NF2 mutations. Results: NF2 gene mutations are implicated in over 11 different cancers, including several CNS tumors, soli-organ tumors, and skin cancer. NF2 acts as a driver mutation in some cancers, as a non-driver mutation in some cancers, and has simple associated mutations with other cancers. In terms of biological pathway involvement, 8 of the 11 cancers with NF2 mutations show evidence of Hippo signaling cascade involvement. Conclusions: Several cancers characterized by mutations in the NF2 gene have associations with the Hippo signaling pathway. However, future studies remain to be done to further elucidate the role of the Hippo signaling pathway in the carcinogenesis of human NF2-mutant tumors. The findings of this review provide insights into the role of NF2 mutations in cancers, Hippo signaling in NF2-mutant cancers, and current gaps in our knowledge regarding the two.<\/jats:p>","DOI":"10.3390\/cancers17010064","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T13:37:51Z","timestamp":1735738671000},"page":"64","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of NF2 Mutation in the Development of Eleven Different Cancers"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9454-6700","authenticated-orcid":false,"given":"Shervin Hosseingholi","family":"Nouri","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Nitturi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ledbetter","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin W.","family":"English","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiemo J.","family":"Klisch","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Jan and Dan Duncan Neurological Research Institute, Texas Children\u2019s Hospital, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-2989","authenticated-orcid":false,"given":"Akash J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Jan and Dan Duncan Neurological Research Institute, Texas Children\u2019s Hospital, Houston, TX 77030, USA"},{"name":"Department of Otolaryngology\u2013Head & Neck Surgery, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","unstructured":"(2024, October 12). Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Mortality\u2014All COD, Aggregated With State, Total U.S. (1969\u20132022) <Katrina\/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Released April 2024, Available online: www.seer.cancer.gov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.7150\/thno.82690","article-title":"Nasopharyngeal carcinoma ecology theory: Cancer as multidimensional spatiotemporal \u201cunity of ecology and evolution\u201d pathological ecosystem","volume":"13","author":"Luo","year":"2023","journal-title":"Theranostics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"119087","DOI":"10.1016\/j.lfs.2021.119087","article-title":"Recent trends in cancer therapy: A review on the current state of gene delivery","volume":"269","author":"Yahya","year":"2021","journal-title":"Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0098-2997(00)00007-8","article-title":"The molecular biology of cancer","volume":"21","author":"Bertram","year":"2000","journal-title":"Mol. Asp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrg3317","article-title":"Evolution of the cancer genome","volume":"13","author":"Yates","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.18632\/oncotarget.26941","article-title":"Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas","volume":"10","author":"Loewenstern","year":"2019","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/humu.20393","article-title":"Mutational spectrum of the NF2 gene: A meta-analysis of 12 years of research and diagnostic laboratory findings","volume":"28","author":"Ahronowitz","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.febslet.2014.04.001","article-title":"Molecular insights into NF2\/Merlin tumor suppressor function","volume":"588","author":"Cooper","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lee, S., Karas, P.J., Hadley, C.C., Bayley V, J.C., Khan, A.B., Jalali, A., Sweeney, A.D., Klisch, T.J., and Patel, A.J. (2019). The Role of Merlin\/NF2 Loss in Meningioma Biology. Cancers, 11.","DOI":"10.3390\/cancers11111633"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18632\/oncotarget.1557","article-title":"NF2\/merlin in hereditary neurofibromatosis 2 versus cancer: Biologic mechanisms and clinical associations","volume":"5","author":"Schroeder","year":"2014","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00439-018-1909-9","article-title":"Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas","volume":"137","author":"Kluwe","year":"2018","journal-title":"Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41467-017-00346-5","article-title":"Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development","volume":"8","author":"Vitte","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng0294-185","article-title":"Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types","volume":"6","author":"Bianchi","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.1320520411","article-title":"Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity","volume":"52","author":"Parry","year":"1994","journal-title":"Am. J. Med. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","article-title":"Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas","volume":"6","author":"Ruttledge","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bachir, S., Shah, S., Shapiro, S., Koehler, A., Mahammedi, A., Samy, R.N., Zuccarello, M., Schorry, E., and Sengupta, S. (2021). Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020690"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas","volume":"133","author":"Youngblood","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.18632\/oncotarget.27841","article-title":"Advances in meningioma genomics, proteomics, and epigenetics: Insights into biomarker identification and targeted therapies","volume":"11","author":"Nazem","year":"2020","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e13120","DOI":"10.1111\/bpa.13120","article-title":"Molecular landscapes of longitudinal NF2\/22q and non-NF2\/22q meningiomas show different life histories","volume":"33","author":"Ng","year":"2023","journal-title":"Brain Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/0008-5472.CAN-20-3669","article-title":"Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development","volume":"81","author":"Najm","year":"2021","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2559.2012.04205.x","article-title":"Neoplastic spindle cells in nasopharyngeal carcinoma show features of epithelial-mesenchymal transition","volume":"61","author":"Luo","year":"2012","journal-title":"Histopathology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial-mesenchymal transition in malignant mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2017.07.009","article-title":"Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas","volume":"380","author":"Wallesch","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.trecan.2019.04.001","article-title":"Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities","volume":"5","author":"Calses","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41556-021-00813-8","article-title":"The Hippo pathway kinases LATS1 and LATS2 attenuate cellular responses to heavy metals through phosphorylating MTF1","volume":"24","author":"Han","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eabj3887","DOI":"10.1126\/sciadv.abj3887","article-title":"LATS1 is a central signal transmitter for achieving full type-I interferon activity","volume":"8","author":"Zuo","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.49.1.267","article-title":"Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas","volume":"49","author":"Gutmann","year":"1997","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9440(10)65158-9","article-title":"Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas","volume":"155","author":"Ebert","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1038\/onc.2010.363","article-title":"Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas","volume":"29","author":"Hadfield","year":"2010","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3171\/2016.10.JNS161384","article-title":"Genetic landscape of sporadic vestibular schwannoma","volume":"128","author":"Bruland","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/NEN.0000000000000238","article-title":"Alterations in the NF2\/LATS1\/LATS2\/YAP Pathway in Schwannomas","volume":"74","author":"Oh","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/brain\/awac342","article-title":"Inhibition of YAP\/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma","volume":"146","author":"Laraba","year":"2023","journal-title":"Brain"},{"key":"ref_35","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yang, H., Hall SR, R., Sun, B., Zhao, L., Gao, Y., Schmid, R.A., Tan, S.T., Peng, R.W., and Yao, F. (2021). NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13071561"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1349-7006.1995.tb03003.x","article-title":"Low incidence of a nucleotide sequence alteration of the neurofibromatosis 2 gene in human breast cancers","volume":"86","author":"Yaegashi","year":"1995","journal-title":"Jpn. J. Cancer Res. Gann"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/1878-0261.12896","article-title":"Merlin deficiency alters the redox management program in breast cancer","volume":"15","author":"Mota","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1073\/pnas.1822155116","article-title":"BRCA1\/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1 signaling","volume":"116","author":"Verma","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1021\/acsnano.1c10921","article-title":"Targeted Intervention of NF2-YAP Signaling Axis in CD24-Overexpressing Cells Contributes to Encouraging Therapeutic Effects in TNBC","volume":"16","author":"Hou","year":"2022","journal-title":"ACS Nano"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1101\/gad.1938710","article-title":"Nf2\/Merlin controls progenitor homeostasis and tumorigenesis in the liver","volume":"24","author":"Benhamouche","year":"2010","journal-title":"Genes Dev."},{"key":"ref_43","first-page":"3650","article-title":"Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"38","author":"Zhang","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"840","DOI":"10.4161\/cbt.25329","article-title":"Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes","volume":"14","author":"Malhotra","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/pros.20760","article-title":"Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells","volume":"68","author":"Horiguchi","year":"2008","journal-title":"Prostate"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/onc.2014.185","article-title":"Oncogenic role of Merlin\/NF2 in glioblastoma","volume":"34","author":"Guerrero","year":"2015","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/neuonc\/nop060","article-title":"Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma","volume":"12","author":"Morales","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00000478-200401000-00012","article-title":"Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence","volume":"28","author":"Sheikh","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1158\/2159-8290.CD-15-0330","article-title":"NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition","volume":"5","author":"Untch","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Murray, L.B., Lau, Y.K., and Yu, Q. (2012). Merlin is a negative regulator of human melanoma growth. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043295"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1016\/j.molcel.2021.07.040","article-title":"Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity","volume":"81","author":"Meng","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1093\/oncolo\/oyad040","article-title":"Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy","volume":"28","author":"Hacking","year":"2023","journal-title":"Oncologist"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","article-title":"YAP\/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells","volume":"49","author":"White","year":"2019","journal-title":"Dev. Cell"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Malouf, G.G., Flippot, R., Dong, Y., Dinatale, R.G., Chen, Y.B., Su, X., Comp\u00e9rat, E., Roupr\u00eat, M., Mano, R., and Blum, K.A. (2020). Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-57534-5"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41698-024-00627-5","article-title":"NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity","volume":"8","author":"Xu","year":"2024","journal-title":"NPJ Precis. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/64\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:42Z","timestamp":1760115342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17010064"],"URL":"https:\/\/doi.org\/10.3390\/cancers17010064","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}